Standard

Are we prepared in case of a possible smallpox-like disease emergence? / Olson, Victoria A.; Shchelkunov, Sergei N.

In: Viruses, Vol. 9, No. 9, 242, 01.09.2017.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Olson VA, Shchelkunov SN. Are we prepared in case of a possible smallpox-like disease emergence? Viruses. 2017 Sept 1;9(9):242. doi: 10.3390/v9090242

Author

Olson, Victoria A. ; Shchelkunov, Sergei N. / Are we prepared in case of a possible smallpox-like disease emergence?. In: Viruses. 2017 ; Vol. 9, No. 9.

BibTeX

@article{545150d28f5648f989fdf3dfbd8298c8,
title = "Are we prepared in case of a possible smallpox-like disease emergence?",
abstract = "Smallpox was the first human disease to be eradicated, through a concerted vaccination campaign led by the World Health Organization. Since its eradication, routine vaccination against smallpox has ceased, leaving the world population susceptible to disease caused by orthopoxviruses. In recent decades, reports of human disease from zoonotic orthopoxviruses have increased. Furthermore, multiple reports of newly identified poxviruses capable of causing human disease have occurred. These facts raise concerns regarding both the opportunity for these zoonotic orthopoxviruses to evolve and become a more severe public health issue, as well as the risk of Variola virus (the causative agent of smallpox) to be utilized as a bioterrorist weapon. The eradication of smallpox occurred prior to the development of the majority of modern virological and molecular biological techniques. Therefore, there is a considerable amount that is not understood regarding how this solely human pathogen interacts with its host. This paper briefly recounts the history and current status of diagnostic tools, vaccines, and anti-viral therapeutics for treatment of smallpox disease. The authors discuss the importance of further research to prepare the global community should a smallpox-like virus emerge.",
keywords = "Antivirals, Smallpox, Vaccine, Variola virus, SPECIES-SPECIFIC DIFFERENCES, NONHUMAN-PRIMATES, antivirals, ANTIPOXVIRUS COMPOUND ST-246, VACCINIA-VIRUS, VARIOLA VIRUS, smallpox, LONG-TERM PROTECTION, REAL-TIME PCR, IN-VITRO EFFICACY, vaccine, COWPOX VIRUS TRANSMISSION, MONKEYPOX-VIRUS",
author = "Olson, {Victoria A.} and Shchelkunov, {Sergei N.}",
year = "2017",
month = sep,
day = "1",
doi = "10.3390/v9090242",
language = "English",
volume = "9",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

RIS

TY - JOUR

T1 - Are we prepared in case of a possible smallpox-like disease emergence?

AU - Olson, Victoria A.

AU - Shchelkunov, Sergei N.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Smallpox was the first human disease to be eradicated, through a concerted vaccination campaign led by the World Health Organization. Since its eradication, routine vaccination against smallpox has ceased, leaving the world population susceptible to disease caused by orthopoxviruses. In recent decades, reports of human disease from zoonotic orthopoxviruses have increased. Furthermore, multiple reports of newly identified poxviruses capable of causing human disease have occurred. These facts raise concerns regarding both the opportunity for these zoonotic orthopoxviruses to evolve and become a more severe public health issue, as well as the risk of Variola virus (the causative agent of smallpox) to be utilized as a bioterrorist weapon. The eradication of smallpox occurred prior to the development of the majority of modern virological and molecular biological techniques. Therefore, there is a considerable amount that is not understood regarding how this solely human pathogen interacts with its host. This paper briefly recounts the history and current status of diagnostic tools, vaccines, and anti-viral therapeutics for treatment of smallpox disease. The authors discuss the importance of further research to prepare the global community should a smallpox-like virus emerge.

AB - Smallpox was the first human disease to be eradicated, through a concerted vaccination campaign led by the World Health Organization. Since its eradication, routine vaccination against smallpox has ceased, leaving the world population susceptible to disease caused by orthopoxviruses. In recent decades, reports of human disease from zoonotic orthopoxviruses have increased. Furthermore, multiple reports of newly identified poxviruses capable of causing human disease have occurred. These facts raise concerns regarding both the opportunity for these zoonotic orthopoxviruses to evolve and become a more severe public health issue, as well as the risk of Variola virus (the causative agent of smallpox) to be utilized as a bioterrorist weapon. The eradication of smallpox occurred prior to the development of the majority of modern virological and molecular biological techniques. Therefore, there is a considerable amount that is not understood regarding how this solely human pathogen interacts with its host. This paper briefly recounts the history and current status of diagnostic tools, vaccines, and anti-viral therapeutics for treatment of smallpox disease. The authors discuss the importance of further research to prepare the global community should a smallpox-like virus emerge.

KW - Antivirals

KW - Smallpox

KW - Vaccine

KW - Variola virus

KW - SPECIES-SPECIFIC DIFFERENCES

KW - NONHUMAN-PRIMATES

KW - antivirals

KW - ANTIPOXVIRUS COMPOUND ST-246

KW - VACCINIA-VIRUS

KW - VARIOLA VIRUS

KW - smallpox

KW - LONG-TERM PROTECTION

KW - REAL-TIME PCR

KW - IN-VITRO EFFICACY

KW - vaccine

KW - COWPOX VIRUS TRANSMISSION

KW - MONKEYPOX-VIRUS

UR - http://www.scopus.com/inward/record.url?scp=85028591894&partnerID=8YFLogxK

U2 - 10.3390/v9090242

DO - 10.3390/v9090242

M3 - Article

C2 - 32962316

AN - SCOPUS:85028591894

VL - 9

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 9

M1 - 242

ER -

ID: 9916152